Daniel Wei-Chen Hong

Daniel Wei-Chen Hong

Neurosurgeon, Founder MOCACARE, CompactCath

“How IoT & AI might impact the future practice of controlling blood pressure”


Out of all life threatening diseases, elevated blood pressure is the most preventable cause of death in US and worldwide. Hypertension causes nearly 400,000 deaths/year in the US and comprises 7% of all global disability-adjusted life-years lost. Patients and clinicians spend a tremendous amount of time talking and thinking about hypertension; nearly 10% of all office visits in the US are hypertension-related. However, missed opportunities for treatment intensification are common in the US, and is a major cause of delay in attainment of blood pressure control.
We will discuss our approach in developing and testing new devices, smartphone apps, and other support systems that aims to effectively engage patients in home monitoring and helps patients and clinicians achieve subsequent blood pressure control.


Daniel Wei-Chen Hong completed his neurosurgeon training in National Taiwan University Hospital in 2006, and since then he applied endoscopic surgery technology in the treatment for hemorrhagic stroke, brain tumor, and intracranial aneurysm. Hong was a visiting assistant professor of neurosurgery at Stanford University from 2010-2012. At Stanford, Hong has applied the principals of design thinking in several interdisciplinary projects, such as Impact and Sustainability of Creative Capacity Building, Design for Service Innovation, Biodesign Innovation for Life, and Robotic Brain Keyhole Surgery.
In 2011, he co-founded CompactCath, a revolutionary urinary catheter solution. In 2014, he co-founded MOCACARE, with the vision to combine health, technology, design, and comfort into medical products and services.